Global Markets Direct’s, ‘Staphylococcus Aureus Infections – Pipeline Review, H2 2015′, provides an overview of the Staphylococcus Aureus Infections’s therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Staphylococcus Aureus Infections, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Staphylococcus Aureus Infections and special features on late-stage and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

• The report provides a snapshot of the global therapeutic landscape of Staphylococcus Aureus Infections
• The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities
• The report reviews key players involved in the therapeutics development for Staphylococcus Aureus Infections and enlists all their major and minor projects
• The report summarizes all the dormant and discontinued pipeline projects
• A review of the Staphylococcus Aureus Infections products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
• Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
• A detailed assessment of monotherapy and combination therapy pipeline projects
• Coverage of the Staphylococcus Aureus Infections pipeline on the basis of target, MoA, route of administration and molecule type
• Latest news and deals relating related to pipeline products

Reasons to buy

• Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
• Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
• Develop strategic initiatives by understanding the focus areas of leading companies
• Identify and understand important and diverse types of therapeutics under development for Staphylococcus Aureus Infections
• Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
• Devise corrective measures for pipeline projects by understanding Staphylococcus Aureus Infections pipeline depth and focus of Indication therapeutics
• Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
• Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Table of Contents

Table of Contents 2
Introduction 8
Staphylococcus aureus Infections Overview 9
Therapeutics Development 10
Staphylococcus aureus Infections - Therapeutics under Development by Companies 12
Staphylococcus aureus Infections - Therapeutics under Investigation by Universities/Institutes 22
Staphylococcus aureus Infections - Pipeline Products Glance 25
Staphylococcus aureus Infections - Products under Development by Companies 29
Staphylococcus aureus Infections - Products under Investigation by Universities/Institutes 42
Staphylococcus aureus Infections - Companies Involved in Therapeutics Development 47
Staphylococcus aureus Infections - Therapeutics Assessment 148
Drug Profiles 160
Staphylococcus aureus Infections - Recent Pipeline Updates 434
Staphylococcus aureus Infections - Dormant Projects 492
Staphylococcus aureus Infections - Discontinued Products 505
Staphylococcus aureus Infections - Product Development Milestones 507
Appendix 513

List of Tables

Number of Products under Development for Staphylococcus aureus Infections, H2 2015 34
Number of Products under Development for Staphylococcus aureus Infections - Comparative Analysis, H2 2015 35
Number of Products under Development by Companies, H2 2015 37
Number of Products under Development by Companies, H2 2015 (Contd..1) 38
Number of Products under Development by Companies, H2 2015 (Contd..2) 39
Number of Products under Development by Companies, H2 2015 (Contd..3) 40
Number of Products under Development by Companies, H2 2015 (Contd..4) 41
Number of Products under Development by Companies, H2 2015 (Contd..5) 42
Number of Products under Development by Companies, H2 2015 (Contd..6) 43
Number of Products under Development by Companies, H2 2015 (Contd..7) 44
Number of Products under Development by Companies, H2 2015 (Contd..8) 45
Number of Products under Investigation by Universities/Institutes, H2 2015 46
Number of Products under Investigation by Universities/Institutes, H2 2015 (Contd..1) 47
Number of Products under Investigation by Universities/Institutes, H2 2015 (Contd..2) 48
Comparative Analysis by Late Stage Development, H2 2015 49
Comparative Analysis by Clinical Stage Development, H2 2015 50
Comparative Analysis by Early Stage Development, H2 2015 51
Comparative Analysis by Unknown Stage Development, H2 2015 52
Products under Development by Companies, H2 2015 53
Products under Development by Companies, H2 2015 (Contd..1) 54
Products under Development by Companies, H2 2015 (Contd..2) 55
Products under Development by Companies, H2 2015 (Contd..3) 56
Products under Development by Companies, H2 2015 (Contd..4) 57
Products under Development by Companies, H2 2015 (Contd..5) 58
Products under Development by Companies, H2 2015 (Contd..6) 59
Products under Development by Companies, H2 2015 (Contd..7) 60
Products under Development by Companies, H2 2015 (Contd..8) 61
Products under Development by Companies, H2 2015 (Contd..9) 62
Products under Development by Companies, H2 2015 (Contd..10) 63
Products under Development by Companies, H2 2015 (Contd..11) 64
Products under Development by Companies, H2 2015 (Contd..12) 65
Products under Investigation by Universities/Institutes, H2 2015 66
Products under Investigation by Universities/Institutes, H2 2015 (Contd..1) 67
Products under Investigation by Universities/Institutes, H2 2015 (Contd..2) 68
Products under Investigation by Universities/Institutes, H2 2015 (Contd..3) 69
Products under Investigation by Universities/Institutes, H2 2015 (Contd..4) 70
Staphylococcus aureus Infections - Pipeline by Absynth Biologics Limited, H2 2015 71
Staphylococcus aureus Infections - Pipeline by Actelion Ltd, H2 2015 72
Staphylococcus aureus Infections - Pipeline by Adenium Biotech ApS, H2 2015 73
Staphylococcus aureus Infections - Pipeline by AIMM Therapeutics B.V., H2 2015 74
Staphylococcus aureus Infections - Pipeline by Alchemia Limited, H2 2015 75
Staphylococcus aureus Infections - Pipeline by Allergan Plc, H2 2015 76
Staphylococcus aureus Infections - Pipeline by AlphaMab Co., Ltd, H2 2015 77
Staphylococcus aureus Infections - Pipeline by Alvogen Korea, H2 2015 78
Staphylococcus aureus Infections - Pipeline by AmpliPhi Biosciences Corporation, H2 2015 79
Staphylococcus aureus Infections - Pipeline by AnGes MG, Inc., H2 2015 80
Staphylococcus aureus Infections - Pipeline by Aphios Corporation, H2 2015 81
Staphylococcus aureus Infections - Pipeline by Arsanis Biosciences GmbH, H2 2015 82
Staphylococcus aureus Infections - Pipeline by AstraZeneca Plc, H2 2015 83
Staphylococcus aureus Infections - Pipeline by Aureogen Biosciences, Inc., H2 2015 84
Staphylococcus aureus Infections - Pipeline by Aurigene Discovery Technologies Limited, H2 2015 85
Staphylococcus aureus Infections - Pipeline by Bharat Biotech International Limited, H2 2015 86
Staphylococcus aureus Infections - Pipeline by BioDiem Ltd, H2 2015 87
Staphylococcus aureus Infections - Pipeline by Biomar Microbial Technologies, H2 2015 88
Staphylococcus aureus Infections - Pipeline by BioSource Pharm, Inc., H2 2015 89
Staphylococcus aureus Infections - Pipeline by C3 Jian, Inc, H2 2015 90
Staphylococcus aureus Infections - Pipeline by Cellceutix Corporation, H2 2015 91
Staphylococcus aureus Infections - Pipeline by Cempra, Inc., H2 2015 92
Staphylococcus aureus Infections - Pipeline by ContraFect Corporation, H2 2015 93
Staphylococcus aureus Infections - Pipeline by CrystalGenomics, Inc., H2 2015 94
Staphylococcus aureus Infections - Pipeline by CSA Biotechnologies LLC , H2 2015 95
Staphylococcus aureus Infections - Pipeline by Daiichi Sankyo Company, Limited, H2 2015 96
Staphylococcus aureus Infections - Pipeline by Debiopharm International S.A., H2 2015 97
Staphylococcus aureus Infections - Pipeline by DesignMedix, Inc., H2 2015 98
Staphylococcus aureus Infections - Pipeline by Destiny Pharma Limited, H2 2015 99
Staphylococcus aureus Infections - Pipeline by Dong-A Socio Group, H2 2015 100
Staphylococcus aureus Infections - Pipeline by Ensol Biosciences Inc., H2 2015 101
Staphylococcus aureus Infections - Pipeline by Evaxion Biotech, H2 2015 102
Staphylococcus aureus Infections - Pipeline by Excelimmune, Inc., H2 2015 103
Staphylococcus aureus Infections - Pipeline by F. Hoffmann-La Roche Ltd., H2 2015 104
Staphylococcus aureus Infections - Pipeline by Galapagos NV, H2 2015 105
Staphylococcus aureus Infections - Pipeline by GangaGen Inc., H2 2015 106
Staphylococcus aureus Infections - Pipeline by GlaxoSmithKline Plc, H2 2015 107
Staphylococcus aureus Infections - Pipeline by Helix BioMedix, Inc., H2 2015 108
Staphylococcus aureus Infections - Pipeline by Hsiri Therapeutics, LLC, H2 2015 109
Staphylococcus aureus Infections - Pipeline by Humabs BioMed SA, H2 2015 110
Staphylococcus aureus Infections - Pipeline by Ildong Pharmaceutical Co., Ltd., H2 2015 111
Staphylococcus aureus Infections - Pipeline by Imaxio SA, H2 2015 112
Staphylococcus aureus Infections - Pipeline by Immupharma Plc, H2 2015 113
Staphylococcus aureus Infections - Pipeline by ImmuVen, Inc., H2 2015 114
Staphylococcus aureus Infections - Pipeline by Integrated BioTherapeutics, Inc., H2 2015 115
Staphylococcus aureus Infections - Pipeline by iNtRON Biotechnology Inc., H2 2015 116
Staphylococcus aureus Infections - Pipeline by ioGenetics, Inc., H2 2015 117
Staphylococcus aureus Infections - Pipeline by Kyorin Pharmaceutical Co., Ltd., H2 2015 118
Staphylococcus aureus Infections - Pipeline by Lascco SA, H2 2015 119
Staphylococcus aureus Infections - Pipeline by LegoChem Biosciences, Inc, H2 2015 120
Staphylococcus aureus Infections - Pipeline by Lytix Biopharma AS, H2 2015 121
Staphylococcus aureus Infections - Pipeline by Madam Therapeutics B.V., H2 2015 122
Staphylococcus aureus Infections - Pipeline by MedImmune, LLC, H2 2015 123
Staphylococcus aureus Infections - Pipeline by Melinta Therapeutics, Inc, H2 2015 124
Staphylococcus aureus Infections - Pipeline by Merck & Co., Inc., H2 2015 125
Staphylococcus aureus Infections - Pipeline by MGB Biopharma Limited, H2 2015 126
Staphylococcus aureus Infections - Pipeline by Microbiotix, Inc., H2 2015 127
Staphylococcus aureus Infections - Pipeline by MicuRx Pharmaceuticals, Inc., H2 2015 128
Staphylococcus aureus Infections - Pipeline by MorphoSys AG, H2 2015 129
Staphylococcus aureus Infections - Pipeline by Morphotek, Inc., H2 2015 130
Staphylococcus aureus Infections - Pipeline by Motif BioSciences, Inc., H2 2015 131
Staphylococcus aureus Infections - Pipeline by Nabriva Therapeutics AG, H2 2015 132
Staphylococcus aureus Infections - Pipeline by NanoBio Corporation, H2 2015 133
Staphylococcus aureus Infections - Pipeline by NovaBay Pharmaceuticals, Inc., H2 2015 134
Staphylococcus aureus Infections - Pipeline by Novabiotics Limited, H2 2015 135
Staphylococcus aureus Infections - Pipeline by NovaDigm Therapeutics, Inc., H2 2015 136
Staphylococcus aureus Infections - Pipeline by Novan, Inc., H2 2015 137
Staphylococcus aureus Infections - Pipeline by NovoBiotic Pharmaceuticals, LLC, H2 2015 138
Staphylococcus aureus Infections - Pipeline by Omnia Molecular Ltd., H2 2015 139
Staphylococcus aureus Infections - Pipeline by Oragenics, Inc., H2 2015 140
Staphylococcus aureus Infections - Pipeline by Pepscan Presto BV, H2 2015 141
Staphylococcus aureus Infections - Pipeline by Pfizer Inc., H2 2015 142
Staphylococcus aureus Infections - Pipeline by PharmaIN Corporation, H2 2015 143
Staphylococcus aureus Infections - Pipeline by Phico Therapeutics Limited, H2 2015 144
Staphylococcus aureus Infections - Pipeline by Phylogica Limited, H2 2015 145
Staphylococcus aureus Infections - Pipeline by Pono Pharma, H2 2015 146
Staphylococcus aureus Infections - Pipeline by Procarta Biosystems Ltd, H2 2015 147
Staphylococcus aureus Infections - Pipeline by QureTech Bio AB, H2 2015 148
Staphylococcus aureus Infections - Pipeline by Redx Pharma Plc, H2 2015 149
Staphylococcus aureus Infections - Pipeline by Sarepta Therapeutics, Inc., H2 2015 150
Staphylococcus aureus Infections - Pipeline by Savara Inc., H2 2015 151
Staphylococcus aureus Infections - Pipeline by Sealife PHARMA GMBH, H2 2015 152
Staphylococcus aureus Infections - Pipeline by Sentinella Pharmaceuticals, Inc., H2 2015 153
Staphylococcus aureus Infections - Pipeline by Soligenix, Inc., H2 2015 154
Staphylococcus aureus Infections - Pipeline by Sorrento Therapeutics, Inc., H2 2015 155
Staphylococcus aureus Infections - Pipeline by Sumitomo Dainippon Pharma Co., Ltd., H2 2015 156
Staphylococcus aureus Infections - Pipeline by Syntiron LLC, H2 2015 157
Staphylococcus aureus Infections - Pipeline by Taejoon Pharm Co., Ltd., H2 2015 158
Staphylococcus aureus Infections - Pipeline by TAXIS Pharmaceuticals, Inc., H2 2015 159
Staphylococcus aureus Infections - Pipeline by Techulon, Inc., H2 2015 160
Staphylococcus aureus Infections - Pipeline by Telephus Medical LLC, H2 2015 161
Staphylococcus aureus Infections - Pipeline by Tetraphase Pharmaceuticals Inc., H2 2015 162
Staphylococcus aureus Infections - Pipeline by TGV-Laboratories, H2 2015 163
Staphylococcus aureus Infections - Pipeline by Theravance Biopharma, Inc., H2 2015 164
Staphylococcus aureus Infections - Pipeline by United Therapeutics Corporation, H2 2015 165
Staphylococcus aureus Infections - Pipeline by Valevia UK Limited, H2 2015 166
Staphylococcus aureus Infections - Pipeline by Varinel, Inc., H2 2015 167
Staphylococcus aureus Infections - Pipeline by Wintermute Biomedical LLC, H2 2015 168
Staphylococcus aureus Infections - Pipeline by Wockhardt Limited, H2 2015 169
Staphylococcus aureus Infections - Pipeline by XBiotech USA, Inc., H2 2015 170
Staphylococcus aureus Infections - Pipeline by Yungjin Pharm. Co., Ltd., H2 2015 171
Assessment by Monotherapy Products, H2 2015 172
Assessment by Combination Products, H2 2015 173
Number of Products by Stage and Target, H2 2015 175
Number of Products by Stage and Mechanism of Action, H2 2015 178
Number of Products by Stage and Route of Administration, H2 2015 181
Number of Products by Stage and Molecule Type, H2 2015 183
Staphylococcus aureus Infections Therapeutics - Recent Pipeline Updates, H2 2015 458
Staphylococcus aureus Infections - Dormant Projects, H2 2015 516
Staphylococcus aureus Infections - Dormant Projects (Contd..1), H2 2015 517
Staphylococcus aureus Infections - Dormant Projects (Contd..2), H2 2015 518
Staphylococcus aureus Infections - Dormant Projects (Contd..3), H2 2015 519
Staphylococcus aureus Infections - Dormant Projects (Contd..4), H2 2015 520
Staphylococcus aureus Infections - Dormant Projects (Contd..5), H2 2015 521
Staphylococcus aureus Infections - Dormant Projects (Contd..6), H2 2015 522
Staphylococcus aureus Infections - Dormant Projects (Contd..7), H2 2015 523
Staphylococcus aureus Infections - Dormant Projects (Contd..8), H2 2015 524
Staphylococcus aureus Infections - Dormant Projects (Contd..9), H2 2015 525
Staphylococcus aureus Infections - Dormant Projects (Contd..10), H2 2015 526
Staphylococcus aureus Infections - Dormant Projects (Contd..11), H2 2015 527
Staphylococcus aureus Infections - Dormant Projects (Contd..12), H2 2015 528
Staphylococcus aureus Infections - Discontinued Products, H2 2015 529
Staphylococcus aureus Infections - Discontinued Products (Contd..1), H2 2015 530

List of Figures

Number of Products under Development for Staphylococcus aureus Infections, H2 2015 34
Number of Products under Development for Staphylococcus aureus Infections - Comparative Analysis, H2 2015 35
Number of Products under Development by Companies, H2 2015 36
Number of Products under Investigation by Universities/Institutes, H2 2015 46
Comparative Analysis by Clinical Stage Development, H2 2015 50
Comparative Analysis by Early Stage Products, H2 2015 51
Assessment by Monotherapy Products, H2 2015 172
Assessment by Combination Products, H2 2015 173
Number of Products by Top 10 Targets, H2 2015 174
Number of Products by Stage and Top 10 Targets, H2 2015 174
Number of Products by Top 10 Mechanism of Actions, H2 2015 177
Number of Products by Stage and Top 10 Mechanism of Actions, H2 2015 177
Number of Products by Top 10 Routes of Administration, H2 2015 180
Number of Products by Stage and Top 10 Routes of Administration, H2 2015 180
Number of Products by Top 10 Molecule Types, H2 2015 182
Number of Products by Stage and Top 10 Molecule Types, H2 2015 182